Bolt Biotherapeutics Inc. (BOLT)
BOLT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/0001193125-26-104121-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BOLT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001641281 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $7.7M |
| Net income | -$33.4M |
| Operating income | -$36.1M |
| Net margin | -433.7% |
| Operating margin | -469.3% |
| Revenue growth | +0.1% |
| Cash | $11.7M |
| Total assets | $56.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The Company has concluded that substantial doubt exists about its ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $13.8M cash; operating cash flow -$6.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 2,607,490 (2026-11-06); 1,919,441 a year earlier; 37,965,870 three years earlier. 3y figure adjusted for split (1-for-20 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2025-06-09 | Source 2025-06-09 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $5K, sold $128K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$4.4M | -$3.1M | $13.8M | No debt tags | $2.5M | 10-Q 2026-11-13 |
| Q2 2026 2026-06-30 | $5K | -$7.5M | -$6.5M | $12.9M | No debt tags | $4.7M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $26K | -$7.7M | -$8.0M | $11.6M | No debt tags | $6.5M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $2.5M | -$6.6M | -$7.2M | $11.7M | No debt tags | $7.7M | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $2.2M | -$7.1M | -$9.7M | $17.8M | No debt tags | $5.2M | 10-Q 2026-11-13 |
| Q2 2025 2025-06-30 | $1.8M | -$8.6M | -$9.6M | $9.6M | No debt tags | $4.2M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $1.2M | -$11.0M | -$13.4M | $8.4M | No debt tags | $3.6M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $0 | -$15.9M | -$14.4M | $7.2M | No debt tags | $7.7M | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2022-04-07 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 300 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.0% |
| 1 month | +41.9% |
| 3 months | +89.4% |
| Year to date | +11.2% |
| 1 year | +29.4% |
| From 52-week high | -14.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AKTX | Akari Therapeutics plc ADS | $6.51 | -4.26% | $15.1M |
| PBM | Psyence Biomedical Ltd. Common Shares | $2.83 | -11.56% | $15.0M |
| CNTX | Context Therapeutics Inc. | $0.1659 | -8.24% | $15.2M |
| ACTU | Actuate Therapeutics Inc. | $0.2680 | -7.59% | $14.7M |
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
| CTXR | Citius Pharmaceuticals Inc. | $0.5276 | -1.40% | $14.5M |
| NCEL | NewcelX Ltd. | $2.75 | +5.36% | $15.9M |
| MCRB | Seres Therapeutics Inc. | $1.41 | +0.71% | $14.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier